Literature DB >> 17884843

A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation.

Kenta Moriwaki1, Katsuhisa Noda, Takatoshi Nakagawa, Michio Asahi, Harumasa Yoshihara, Naoyuki Taniguchi, Norio Hayashi, Eiji Miyoshi.   

Abstract

Changes in the levels of fucosylation regulate the biological phenotype of cancer cells and a specific fucosylation, such as fucosylated alpha-fetoprotein (AFP-L3) has been clinically used as a tumor marker for hepatocellular carcinoma (HCC). However, detailed molecular mechanisms that explain the increased fucosylation in HCC remain unknown despite 10 years of study by these researchers. Fucosylation is regulated by complicated mechanisms that involve several factors: fucosyltransferases, GDP-fucose transporter (GDP-Fuc Tr), and synthetic enzymes of GDP-fucose, such as GDP-mannose 4, 6-dehydratase (GMD), GDP-4-keto-6-deoxy-mannose-3, 5-epimerase-4-reductase (FX), and GDP-fucose pyrophosphorylase. In this study, the expression of fucosylation-related genes in HCC tissues was studied and it was found that GDP-Fuc Tr is a key factor for increases in fucosylation. A real-time reverse transcription polymerase chain reaction (RT-PCR) analysis showed significant increases in GDP-Fuc Tr and FX expression in HCC, and levels of the GMD protein were upregulated by posttranslational modification in HCC tissues. In vitro cell experiments showed that the level of GDP-Fuc Tr was the most significantly correlated with the level of cellular fucosylation and the overexpression of GDP-Fuc Tr dramatically increased fucosylation in Hep3B cells. The importance of GDP-Fuc Tr in the increase of fucosylation was also confirmed with immunohistochemical analyses. These findings suggest that the upregulation of GDP-Fuc Tr plays a pivotal role in increased fucosylation in HCC and represents an attractive target for new treatments and diagnosis for HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884843     DOI: 10.1093/glycob/cwm094

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  25 in total

Review 1.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Pathogenic Variants in Fucokinase Cause a Congenital Disorder of Glycosylation.

Authors:  Bobby G Ng; Jill A Rosenfeld; Lisa Emrick; Mahim Jain; Lindsay C Burrage; Brendan Lee; William J Craigen; David R Bearden; Brett H Graham; Hudson H Freeze
Journal:  Am J Hum Genet       Date:  2018-11-29       Impact factor: 11.025

3.  Negative feedback regulation of Wnt signaling via N-linked fucosylation in zebrafish.

Authors:  Lei Feng; Hao Jiang; Peng Wu; Florence L Marlow
Journal:  Dev Biol       Date:  2014-09-18       Impact factor: 3.582

4.  Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.

Authors:  Naoko Terao; Shinji Takamatsu; Tomomi Minehira; Tomoaki Sobajima; Kotarosumitomo Nakayama; Yoshihiro Kamada; Eiji Miyoshi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

5.  Neural-specific α3-fucosylation of N-linked glycans in the Drosophila embryo requires fucosyltransferase A and influences developmental signaling associated with O-glycosylation.

Authors:  Dubravko Rendić; Mary Sharrow; Toshihiko Katoh; Bryan Overcarsh; Khoi Nguyen; Joseph Kapurch; Kazuhiro Aoki; Iain B H Wilson; Michael Tiemeyer
Journal:  Glycobiology       Date:  2010-08-05       Impact factor: 4.313

6.  Fucosylation and gastrointestinal cancer.

Authors:  Kenta Moriwaki; Eiji Miyoshi
Journal:  World J Hepatol       Date:  2010-04-27

7.  Overexpression of α1,6-fucosyltransferase in hepatoma enhances expression of Golgi phosphoprotein 2 in a fucosylation-independent manner.

Authors:  Sayuri Kawamoto; Kenta Moriwaki; Tsutomu Nakagawa; Mika Terao; Shinichiro Shinzaki; Naoko Yamane-Ohnuki; Mitsuo Satoh; Anand S Mehta; Timothy M Block; Eiji Miyoshi
Journal:  Int J Oncol       Date:  2011-04-14       Impact factor: 5.650

8.  Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations.

Authors:  Yashu Liu; Jintang He; Chen Li; Ricardo Benitez; Sherry Fu; Jorge Marrero; David M Lubman
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

Review 9.  Aberrant PSA glycosylation--a sweet predictor of prostate cancer.

Authors:  Sarah Gilgunn; Paul J Conroy; Radka Saldova; Pauline M Rudd; Richard J O'Kennedy
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

10.  The Drosophila neurally altered carbohydrate mutant has a defective Golgi GDP-fucose transporter.

Authors:  Christoph Geisler; Varshika Kotu; Mary Sharrow; Dubravko Rendić; Gerald Pöltl; Michael Tiemeyer; Iain B H Wilson; Donald L Jarvis
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.